Mabwell (Shanghai) Bioscience's (SHA:688062, HKG:2493) clinical trial application for 9MW5211 as treatment of vitiligo has been approved by China's National Medical Products Administration.
The approval allows the company to proceed with clinical trials of 9MW5211 for the indication, according to a Wednesday Hong Kong bourse filing.
Shares of the company rose nearly 1% in recent trade.